Beyond manufacturing capacity, sponsors seek expertise in specialized drug formulations, regulatory affairs, and service ...

Novo Nordisk’s majority shareholder Novo Holdings is buying Catalent for $16.5 billion, and then selling the three fill-and-finish facilities in the US, Belgium, and Italy to Novo Nordisk for ...

The takeover also means that a related $11 billion transaction in which Novo Holdings' subsidiary Novo Nordisk takes control of three of Catalent’s fill-and-finish facilities in Italy ...

Galapagos, based in Mechelen, Belgium, is developing cell therapies for blood cancers ... In January, Galapagos partnered with another CDMO, Catalent, to use its commercial cell therapy manufacturing ...

SOMERSET, N.J., February 20, 2025--(BUSINESS WIRE)--Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has ...

Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through ...

Developers have broken ground and are marketing a new industrial shell building they expect to be completed by the summer, the Greenville ENC Alliance economic development partnership announced ...

BRUSSELS — As a wave of violence rocks Brussels, struggling law enforcement agencies need more support from Belgian authorities to cope, the city’s public prosecutor said Tuesday. “The situation is ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...